Expertise in
25
conditions

Dr. Ibrahim Aldoss

Oncology
Ibrahim T. Aldoss, M.D.
1500 Duarte Rd, 
Duarte, CA 
Clinical Trials:Currently Recruiting for 2 Trials
Expertise in
25
conditions
Ibrahim T. Aldoss, M.D.
1500 Duarte Rd, 
Duarte, CA 

Overview

Ibrahim Aldoss is an Oncologist practicing medicine in Duarte, California.

Dr. Aldoss is highly rated in 25 conditions, according to our data. His clinical expertise encompasses Acute Lymphoblastic Leukemia (ALL), Leukemia, Acute Myeloid Leukemia (AML), Bone Marrow Aspiration, and Bone Marrow Transplant.

He is actively involved in clinical research, co-authoring 228 peer reviewed articles and participating in 14 clinical trials.

Specialties

Oncology

Licenses

Internal Medicine in NE

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Highmark
  • EPO
  • HMO
  • PPO
HMSA
  • HMO
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
LA Care
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Silversummit Health Plan
  • HMO
  • MANAGED MEDICAID PLAN
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

Ibrahim T. Aldoss, M.D.
1500 Duarte Rd, Duarte, CA 91010
Other Locations
City Of Hope Comprehensive Cancer Center-Duarte
1500 Duarte Rd, Duarte, CA 91010

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

14 Clinical Trials

A Phase II Study of Inotuzumab Ozogamicin Followed by Blinatumomab for Ph-Negative, CD22-Positive B-Lineage Acute Lymphoblastic Leukemia in Newly Diagnosed Older Adults or Adults With Relapsed or Refractory Disease
A Phase II Study of Inotuzumab Ozogamicin Followed by Blinatumomab for Ph-Negative, CD22-Positive B-Lineage Acute Lymphoblastic Leukemia in Newly Diagnosed Older Adults or Adults With Relapsed or Refractory Disease
Enrollment Status: Recruiting
Publish Date: April 13, 2026
Intervention Type: Procedure, Biological, Drug
Study Drugs: Blinatumomab, Inotuzumab
Study Phase: Phase 2
A Phase I/II Study of AKR1C3-Activated Prodrug OBI-3424 (OBI-3424) In Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL)/T-Cell Lymphoblastic Lymphoma (T-LBL)
A Phase I/II Study of AKR1C3-Activated Prodrug OBI-3424 (OBI-3424) In Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL)/T-Cell Lymphoblastic Lymphoma (T-LBL)
Enrollment Status: Recruiting
Publish Date: August 15, 2025
Intervention Type: Procedure, Drug
Study Drug: AKR1C3-Activated Prodrug OBI-3424
Study Phase: Phase 1/Phase 2
A Phase 2 Study of Blinatumomab and POMP (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) for Patients >/= 65 Years of Age With Newly Diagnosed Philadelphia-Chromosome Negative (Ph-) Acute Lymphoblastic Leukemia (ALL) and of Dasatinib, Prednisone and Blinatumomab for Patients >/= 65 Years of Age With Newly Diagnosed Philadelphia-Chromosome Positive (Ph+) ALL, Relapsed/Refractory Ph+ ALL, and Philadelphia-Chromosome-Like Signature (Ph-Like) ALL (Newly Diagnosed or Relapsed/Refractory) With Known or Presumed Activating Dasatinib-Sensitive Mutations or Kinase Fusions (DSMKF)
A Phase 2 Study of Blinatumomab and POMP (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) for Patients >/= 65 Years of Age With Newly Diagnosed Philadelphia-Chromosome Negative (Ph-) Acute Lymphoblastic Leukemia (ALL) and of Dasatinib, Prednisone and Blinatumomab for Patients >/= 65 Years of Age With Newly Diagnosed Philadelphia-Chromosome Positive (Ph+) ALL, Relapsed/Refractory Ph+ ALL, and Philadelphia-Chromosome-Like Signature (Ph-Like) ALL (Newly Diagnosed or Relapsed/Refractory) With Known or Presumed Activating Dasatinib-Sensitive Mutations or Kinase Fusions (DSMKF)
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Procedure, Drug, Biological
Study Drugs: Blinatumomab, Dasatinib, Mercaptopurine, Methotrexate, Methotrexate Sodium, Prednisone, Vincristine, Vincristine Sulfate
Study Phase: Phase 2
A Phase 1 Trial to Evaluate the Safety of Single Agent Flotetuzumab in Advanced CD123-Positive Hematological Malignancies
A Phase 1 Trial to Evaluate the Safety of Single Agent Flotetuzumab in Advanced CD123-Positive Hematological Malignancies
Enrollment Status: Completed
Publish Date: January 28, 2026
Intervention Type: Drug, Biological
Study Drugs: Acetaminophen, Dexamethasone, Diphenhydramine, Ibuprofen, Ranitidine, Flotetuzumab
Study Phase: Phase 1
A Phase 3, Randomized, Open-label, Multicenter Study Comparing Ponatinib Versus Imatinib, Administered in Combination With Reduced-Intensity Chemotherapy, in Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
A Phase 3, Randomized, Open-label, Multicenter Study Comparing Ponatinib Versus Imatinib, Administered in Combination With Reduced-Intensity Chemotherapy, in Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
Enrollment Status: Active_not_recruiting
Publish Date: November 26, 2025
Intervention Type: Drug
Study Drugs: Ponatinib, Imatinib, Vincristine, Dexamethasone, Cytarabine, Methotrexate, Prednisone
Study Phase: Phase 3
A Phase II Study of IRD (Ixazomib, Lenalidomide, & Dexamethasone) for Consolidation Therapy Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma
A Phase II Study of IRD (Ixazomib, Lenalidomide, & Dexamethasone) for Consolidation Therapy Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma
Enrollment Status: Active_not_recruiting
Publish Date: November 10, 2025
Intervention Type: Drug, Biological
Study Drugs: Ixazomib, Lenalidomide, Dexamethasone
Study Phase: Phase 2
A Phase 1 Dose-Escalation and Dose-Expansion Study of Anti-CD7 Allogeneic CAR-T Cell Therapy (WU-CART-007) in Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL)/Lymphoblastic Lymphoma (LBL)
A Phase 1 Dose-Escalation and Dose-Expansion Study of Anti-CD7 Allogeneic CAR-T Cell Therapy (WU-CART-007) in Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL)/Lymphoblastic Lymphoma (LBL)
Enrollment Status: Completed
Publish Date: September 30, 2025
Intervention Type: Biological
Study Drug: WU-CART-007
Study Phase: Phase 1
A Phase 2 Study of MLN0128 (TAK-228) in Relapsed and/or Refractory Acute Lymphoblastic Leukemia (ALL)
A Phase 2 Study of MLN0128 (TAK-228) in Relapsed and/or Refractory Acute Lymphoblastic Leukemia (ALL)
Enrollment Status: Completed
Publish Date: March 03, 2025
Intervention Type: Other, Drug
Study Drug: Sapanisertib
Study Phase: Phase 2
A Phase 1/2, First in Human, Dose Escalation Study of MGD006, a CD123 x CD3 DART® Bi-Specific Antibody Based Molecule, in Patients With Relapsed or Refractory AML or Intermediate-2/High Risk Myelodysplastic Syndrome (MDS)
A Phase 1/2, First in Human, Dose Escalation Study of MGD006, a CD123 x CD3 DART® Bi-Specific Antibody Based Molecule, in Patients With Relapsed or Refractory AML or Intermediate-2/High Risk Myelodysplastic Syndrome (MDS)
Enrollment Status: Terminated
Publish Date: January 30, 2024
Intervention Type: Biological, Drug
Study Drug: Flotetuzumab
Study Phase: Phase 1/Phase 2
A Phase 1 / 2 Study to Evaluate the Safety, Tolerability and Initial Anti-Tumor Activity of Adoptively Transferred T Lymphocytes Targeting WT1, PRAME and Cyclin A1 AML or MDS Patients With Relapsed Disease After Matched Allogeneic HCT
A Phase 1 / 2 Study to Evaluate the Safety, Tolerability and Initial Anti-Tumor Activity of Adoptively Transferred T Lymphocytes Targeting WT1, PRAME and Cyclin A1 AML or MDS Patients With Relapsed Disease After Matched Allogeneic HCT
Enrollment Status: Unknown
Publish Date: January 16, 2024
Intervention Type: Biological
Study Drug: NEXI-001 T Cell Infusion
Study Phase: Phase 1/Phase 2
View 8 Less Clinical Trials

228 Total Publications

Disability-Free Survival: A Novel Morbidity Endpoint for Older Adult Allogeneic Hematopoietic Cell Transplantation.
Disability-Free Survival: A Novel Morbidity Endpoint for Older Adult Allogeneic Hematopoietic Cell Transplantation.
Journal: Transplantation and cellular therapy
Published: January 30, 2026
Similar Doctors
Expertise in
26
conditions
Dr. Alex Herrera
Oncology
Expertise in
26
conditions
Dr. Alex Herrera
Oncology

Alex Herrera, M.D.

1500 Duarte Rd, 
Duarte, CA 
 (36.0 miles away)
800-826-4673
Experience:
17+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Alex Herrera is an Oncologist practicing medicine in Duarte, California. He has been practicing medicine for over 17 years. Dr. Herrera is highly rated in 26 conditions, according to our data. His clinical expertise encompasses Hodgkin Lymphoma, Classical Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Herrera is board certified in American Board Of Internal Medicine, Hematology and American Board Of Internal Medicine, Oncology.

Expertise in
16
conditions
Dr. Alexey Danilov
Oncology
Expertise in
16
conditions
Dr. Alexey Danilov
Oncology

Alexey Danilov, M.D., PH.D.

1500 Duarte Rd, 
Duarte, CA 
 (36.0 miles away)
800-826-4673
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Alexey Danilov is an Oncologist practicing medicine in Duarte, California. Dr. Danilov is highly rated in 16 conditions, according to our data. His clinical expertise encompasses Mantle Cell Lymphoma (MCL), Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), Bone Marrow Transplant, and Bone Marrow Aspiration.

Expertise in
38
conditions
Dr. Ryotaro Nakamura
Oncology
Expertise in
38
conditions
Dr. Ryotaro Nakamura
Oncology

Ryotaro Nakamura, M.D.

1500 Duarte Rd, 
Duarte, CA 
 (36.0 miles away)
800-826-4673
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Ryotaro Nakamura is an Oncologist practicing medicine in Duarte, California. Dr. Nakamura is highly rated in 38 conditions, according to our data. His clinical expertise encompasses Graft Versus Host Disease (GvHD), Chronic Graft Versus Host Disease (cGvHD), Myelodysplastic Syndrome (MDS), Bone Marrow Transplant, and Bone Marrow Aspiration.

Frequently Asked Questions about Dr. Ibrahim Aldoss

How do I make an appointment with Dr. Ibrahim Aldoss?

You can book an appointment with Dr. Ibrahim Aldoss by calling their office at 800-826-4673. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Ibrahim Aldoss a top-rated expert for Acute Lymphoblastic Leukemia (ALL)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Ibrahim Aldoss is classified as an Elite expert for Acute Lymphoblastic Leukemia (ALL), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Ibrahim Aldoss specialize in?

While Dr. Ibrahim Aldoss is a Oncology, they have specific expertise in Acute Lymphoblastic Leukemia (ALL), Leukemia, and Acute Myeloid Leukemia (AML). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Ibrahim Aldoss participate in research or clinical trials?

Yes. Dr. Ibrahim Aldoss has published 228 articles and abstracts on conditions like Acute Lymphoblastic Leukemia (ALL). You can view a list of Dr. Ibrahim Aldoss's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Ibrahim Aldoss accept my insurance?

Dr. Ibrahim Aldoss accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 800-826-4673 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Aldoss's expertise for a condition
ConditionClose
View All 17 Advanced Conditions
View All 42 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile